ZIC5 Antibody
Description
Introduction to ZIC5 and Its Role in Cancer Biology
ZIC5 (zinc finger of the cerebellum 5) is a transcription factor belonging to the ZIC family, characterized by C2H2-type zinc finger domains. It plays critical roles in embryonic development but is also implicated in oncogenesis across multiple cancer types, including prostate cancer (PCa), hepatocellular carcinoma (HCC), melanoma, and colorectal cancer (CRC). ZIC5 promotes tumor progression by regulating cell proliferation, migration, invasion, and drug resistance through mechanisms involving PDGFD (platelet-derived growth factor D), FAK (focal adhesion kinase), and STAT3 signaling pathways .
ZIC5 Antibody: Definition and Applications
ZIC5 antibodies are polyclonal or monoclonal immunoglobulins designed to detect ZIC5 protein expression in research and diagnostic settings. These reagents enable precise localization and quantification of ZIC5 in tissues or cells using techniques such as:
-
ELISA (Enzyme-Linked Immunosorbent Assay): For quantifying ZIC5 levels in lysates.
-
IHC (Immunohistochemistry): For visualizing ZIC5 in tissue sections.
-
Western Blot (WB): For analyzing ZIC5 protein size and abundance in cell lysates .
ZIC5 Expression in Cancer Tissues
ZIC5 antibodies have revealed elevated ZIC5 expression in aggressive cancers:
-
Prostate Cancer: High ZIC5 levels correlate with metastasis and poor prognosis. IHC studies using ZIC5 antibodies identified enhanced AR (androgen receptor) signaling in metastatic lesions .
-
Hepatocellular Carcinoma (HCC): ZIC5 overexpression in HCC tissues (vs. adjacent normal liver) associates with advanced TNM stages and reduced survival .
-
Melanoma: ZIC5 antibodies detected high ZIC5 levels linked to E-cadherin suppression, epithelial-mesenchymal transition (EMT), and drug resistance .
Functional Studies Using ZIC5 Antibodies
-
PDGFD/FAK/STAT3 Axis: ZIC5 knockdown (validated via WB) reduced PDGFD expression, FAK/STAT3 phosphorylation, and chemoresistance in PCa/CRC models .
-
Therapeutic Targeting: Combined inhibition of ZIC5 and AR (prostate cancer) or BRAF inhibitors (melanoma) enhanced apoptosis and reduced tumor growth in preclinical models .
Clinical and Therapeutic Implications
ZIC5 antibodies serve as tools for:
-
Biomarker Discovery: Identifying ZIC5 as a prognostic marker for HCC and PCa .
-
Drug Development: Validating therapeutic strategies targeting ZIC5-PDGFD-FAK/STAT3 feedback loops.
-
Diagnostic Applications: IHC-based detection of ZIC5 in clinical samples to guide personalized therapies .
Table 1: Antibody Performance in Human Tissues
| Antibody | Tested Tissues | Observed Bands (WB) | IHC Staining Patterns |
|---|---|---|---|
| OAEB00858 | Prostate, Skin, Small Intestine | ~45 kDa (blocked by peptide) | Cytoplasmic/Nuclear |
| NBP2-84346 | Cerebellum | ~45 kDa | Nuclear |
Note: Predicted ZIC5 molecular weight is 68.4 kDa, but observed bands may vary due to post-translational modifications .
Table 2: Experimental Applications of ZIC5 Antibodies
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- hsa_circ_0007534 acts as an oncogene in glioma by promoting ZIC5 expression through suppression of miR-761 availability. PMID: 29605301
- ZIC5 positively regulates the proliferation, migration, and survival of prostate colorectal cancer cells. PMID: 29024195
- ZIC5 is significantly upregulated in non-small cell lung cancer tumor tissues and may function as an oncogene by influencing CCNB1 and CDK1 complex expression. PMID: 27663664
- ZIC1, ZIC2, and ZIC5 may play roles in meningiomas. PMID: 20199689
- The smallest 13q deletion associated with DWM further narrows the previously established critical region for this brain malformation to 13q32.2-32.3. Among the few genes in the deleted region, ZIC2 and ZIC5 appear to be the most likely candidates. PMID: 20683983
